TROG_2014_ASM-program

TROG 201426th ANNUAL SCIENTIFIC MEETING 14TROG 201415 26th ANNUAL SCIENTIFIC MEETINGTROG - FRO TRAINEE STATISTICS& RESEARCH WORKSHOP1st April 2014, 8.30 to 5.00pm, Wandiny Room8.30 - 8.40am Welcome and IntroductionsTime Topic Content8.40 - 9.20am Study Design Cohort/Case controlAspects of biasPhase I and Phase II designsRandomised controlled trialsRandomisation and StratificationNon-inferiority / equivalence designs9.20 - 10.30am Small Groups Example trial scenarios provided will be used in thissession to explore aspects of phase II and III trial designincluding non-inferioirty and equivalence studies10.30 - 11.00am Morning Tea11.00 - 11.40am Selecting endpoints Outcome to EndpointEndpoint selectionMeasurementof effectMeans, mediansStandard deviation, IQROdds ratiosRisk rateHazard ratios - use example of TROG 02.0211.40 - 12.30pm Small Groups Example trial scenarios provided will be used in thissession to explore aspects of endpoint selection12.30 - 1.20pm Lunch1.20pmInternational Guest Speaker - Prof David Brizel2.30 - 3.00pm Other issues Sample size considerationsNon-complianceConfounders – eg HPV, Quality assurance in H&N RT trialsAppropriate follow up timeFrequency of data collectionDealing with missing data3.00 - 3.30pm Afternoon Tea3.30 - 4.30pm Small Groups Example trial scenarios provided will be used in thissession to explore aspects of sample size calculation,follow-up and interpretation4.30 - 5.00pm Q&AWrap-upThis workshop is sponsored by

TROG 201426th ANNUAL SCIENTIFIC MEETING 16TROG 201417 26th ANNUAL SCIENTIFIC MEETING26th ANNUAL SCIENTIFICMEETING PROGRAMMEWEDNESDAY 2nd APRIL 2014Wandiny RoomRegistration from 7.15am to 5.00pm7.30 - 8.15am Breakfast Symposium: Oncology Cancer Care& Global InformaticsPlatinum Sponsor:Varian Medical Systems Australasia8.15 - 8.30am WelcomeConvenor Welcome: Bryan BurmeisterWelcome to Country: Margaret Lawton (Aunty Margaret)Official Opening: Dr Chris Davis, Deputy Minister ofHealth, Queensland8.30 - 9.00am Guest Speaker: Surgery after high dose radiotherapy -do we need super surgeons?Brett MackenzieChair:B BurmeisterM Smithers9.00 - 9.40am Gastrointestinal Chair:B Burmeister9.00am9.05am9.15am9.20am9.30am08.08 (TOPGEAR): A randomised phase III trial ofpreoperative chemoradiotherapy versus preoperativechemotherapy for resectable gastric cancer (Open)03.01 A randomised phase III study in advancedoesophageal cancer to compare quality of life andpalliation of dysphagia in patients treated with radiotherapyversus chemoradiotherapy (closed to follow up)13.02 (LIGHT): Stereotactic body radiotherapy for livermetastases (Approved for Activation)09.01 (PROArCT): A phase II trial of integrated preoperativeradiotherapy and chemotherapy with Oxaliplatin 5-FUand Folinic acid in patients with locally advanced rectalcancer (Closed)01.04: Phase III study of preoperative radiotherapyand chemotherapy for T3 adenocarcinoma of rectum(Closed)T LeongM PennimentD PryorS NganS Ngan9.40 - 10.40am Breast Chair:P O’Brien9.40am9.45am9.50am9.55am10.05am10.10am07.01 (DCIS): A randomised phase III study of radiationdoses and fractionation schedules for ductal carcinomain situ (DCIS) of the breast (Open)12.02 (PET-LABRADOR): A phase II trial of the feasibilityof breast conservation for locally advanced breastcancer using MRI and PET scanning to predict conservability,local control and disease free survival (Approvedfor Activation)08.06 (STARS): A randomised comparison of Anastrozolecommenced before and continuing during adjuvantradiotherapy for breast cancer versus Anastrozole andsubsequent anti-oestrogen therapy delayed until afterradiotherapy (Open)10.02 (RAPID): A randomised Trial of Accelerated PartialBreast Irradiation (Closed)TROG SEINSATION: occult breast cancer study(Approved for Development)06.02 (APBI): A multicentre feasibility study of threedimensionalconformal radiation therapy for acceleratedpartial breast irradiationB ChuaV AhernP GrahamB ChuaP GrahamB Chua10.20am Guest Speaker: “How to attain $ from Grant$” K Whelan10.40 - 11.00am Morning Tea11.00 - 12.45pm New Proposals: Category A(Trials to be voted on by Full Members)11.00am11.20am11.35am11.55am12.10pm12.30pmHART: Deep Inhalation Breath Hold radiotherapy forpatients with left sided breast cancerDiscussant(10 minute presentation and 5 minute discussion)VPA for GBM: Investigation of adjuvant sodiumvalproate in the treatment of glioblastomaDiscussant(10 minute presentation and 5 minute discussion)SPARK: Stereotactic Prostate Adaptive Radiotherapyutilising KIM (Kilovoltage Intrafraction Monitoring)Discussant(10 minute presentation and 5 minute discussion)Chair:F ForoudiT KronP O’BrienM FayD RoosP KeallJ MartinM Bailey

TROG 201426th ANNUAL SCIENTIFIC MEETING 18TROG 201419 26th ANNUAL SCIENTIFIC MEETING12.45 - 1.05pm New Proposals: Category A Research Projects Chair:F Foroudi12.45pm12.55pm1.05 - 2.00pm LunchRADAR Sub-Study: Survivorship sub-study of theRADAR trialRANZAR: Registry of Australian and New ZealandAblative RadiotherapyJ DenhamJ Ruben1.05 - 1.30pm TROG 08.06 (STARS) Trial Management Committee P Graham1.05 - 1.50pm SPARK: Stereotactic Prostate Adaptive Radiotherapyutilising KIM (Kilovoltage Intrafraction Monitoring)P Keall1.30 - 2.00pm TROG 03.01 Trial Management Committee M Penniment1.15 - 2.00pm TROG New Technologies and Techniques Committee T Kron1.30 - 2.00pm TROG 05.01 (POST) Trial Management Committee S Porceddu1.30 - 2.00pm TROG 07.01 (DCIS) Trial Management Committee B Chua2.00 - 2.40pm Bladder Chair:D Christie2.00pm2.10pm2.20pm2.30pm10.01 (BOLART): Multi-Centre Feasibility study ofOnline Adaptive Image Guided Radiotherapy for MuscleInvasive Bladder Cancer (Closed)02.03: Multicentre Phase III study comparing radicalsynchronous chemo-radiation vs radical radiationalone in the definitive management of muscle invasiveof the urinary bladder following maximal TUR(Closed)RAIDER-B: A randomised phase III trial of adaptiveimage guided standard or dose escalated radiotherapyin the treatment of transitional cell carcinoma of thebladder (Approved for Development)BOB-RT: Better Outcomes for Palliative Radiotherapy ofBladder Cancer (Approved for Development)F ForoudiK GognaF ForoudiA Capp2.40 - 3.00pm Symptom Management Chair:D Christie2.40pm03.08 (NCIC SC.20): A phase III internationalrandomised trial of single versus multiple fractionsfor re-irradiation of painful bone metastases (Closed)D Roos3.00 - 3.20pm Innovations in Research Chair:D Christie3.00pm Innovations in TROG QA J Hatton3.10pmimagine3.20- 3.40pm Afternoon TeaTranslational Research in the context of a Co-operativeClinical Trial OrganisationH Elsaleh3.40 - 5.00pm Annual General Meeting Chair:S Porceddu7.00 - 11.00pm Gala Dinner sponsored by BrainLab...advanced technology withthe patient in mindWith Elekta, it’s reality.Every day, more than 100,000 patients worldwide are diagnosed, treated orreceive follow-up with the help of an oncology or neurosurgery solution fromElekta. Through innovation and collaboration, we are advancing patient care.Human care makes the future possibleMore at elekta.com.auNeuroscienceTreatment Planning& Information SoftwareOncologyBrachytherapy

TROG 201426th ANNUAL SCIENTIFIC MEETING 20TROG 201421 26th ANNUAL SCIENTIFIC MEETINGTHURSDAY 3rd APRIL 20148.55 - 10.05am Prostate Chair:S Porceddu8.55am9.00am9.15am9.30am03.06 (TOAD): A collaborative randomised phase III trial:The timing of intervention with androgen deprivation inprostate cancer patients with a rising PSA (Closed)96.01: Randomised trial investigating the effectivenessof different durations of maximal androgen deprivationprior to and during definitive radiation therapy forlocally advanced carcinoma of the prostate (Closed)03.04 (RADAR): A collaborative randomised phase III trial:The timing of intervention with androgen deprivation inprostate cancer patients with a rising PSA (Closed)08.03 (RAVES): Radiotherapy – Adjuvant Versus EarlySalvage (Open)G DuchesneJ DenhamJ DenhamK Wiltshire9.35am 08.03 (RAVES DA): Decision Aid Study P Sundaresan9.40amGuest Speaker: Proscare: “A psychological care modelfor men with prostate cancer”S Chambers10.05 - 11.00am Head & Neck Chair:G Duchesne10.05am10.10am10.20am10.25am10.30am11.00 - 11.30am Morning Tea12.03 (EAT): Eating As Treatment - An RCT ofpsychological training for dieticians to reducemalnutrition and depression in Head and Neck (Open)07.03 (RadioHUM): Radiotherapy with Humidification inhead and neck cancer (Closed)07.04: A Phase I/II study of cetuximab, carboplatin andradiotherapy for patients with locally advanced Headand Neck Squamous Cell Carcinoma (Closed)12.01 (HPV): A randomised trial of radiation withcetuximab or weekly cisplatin in low risk locoregionallyadvanced HPV-associated oropharyngeal cancer (Open)Guest Speaker: The Clinical Trials Portfolio of the NCIHead and Neck Steering CommitteeC WrattenA MacannJ CorryD RischinJ CorryD Brizel11.30 - 12.10pm Lymphoma Chair:F Hegi-Johnson11.30am99.03: A Randomised Multicentre Trial Of InvolvedField Radiotherapy Versus Involved Field RadiotherapyPlus Chemotherapy in combination with Rituximab(MabThera®) For Stage I – II Low Grade FollicularLymphoma (Closed)TBC11.40am11.45am05.02: A prospective single arm trial of involved fieldradiotherapy alone for stage I-II low grade non-gastricmarginal zone lymphoma (Open)01.02: Phase II study of Idarubicin based combinedmodality therapy in primary central nervous systemlymphoma (Closed)TBCP O’Brien11.55am “Grant Successes - Preparation or Luck” T Leong12.10 - 12.50pm New Proposals: Category B Chair:F Foroudi12.10pm12.20pm12.30pm12.40pm12.50 - 2.00pm LunchA randomised trial of regional nodal irradiationfollowing sentinel lymph node biopsy alone (LeadGroup: NCIC)ENZARAD: Randomised phase III trial of radiation plusandrogen deprivation therapy with or without enzalutamidefor high-risk, clinically localised, prostate cancer(Lead Group: ANZUP)Phase III study of observation vs adjuvant RT forSimpson

TROG 201426th ANNUAL SCIENTIFIC MEETING 222.25 - 2.55pm New Proposals Revisited Chair:F Foroudi2.25pm2.35pm2.45pmHART: Deep Inhalation Breath Hold radiotherapy forpatients with left sided breast cancerVPA for GBM: Investigation of adjuvant sodiumvalproate in the treatment of glioblastomaSPARK: Stereotactic Prostate Adaptive Radiotherapyutilising KIM (Kilovoltage Intrafraction Monitoring)2.55 - 3.00pm New Proposals: Final Summary ofTrial Design/ Discussion and Voting(Closed Session - TROG Members Only)3.00 - 7.00pm Afternoon Activity and Beach BarbequeT KronM FayP KeallJ MartinChair:F ForoudiGenesisCare expands cancerservices in QueenslandGenesisCare has acquired Premion, creatingthe largest cancer care network in Australia.GenesisCare offers treatment for both publicly orprivately referred patients, with immediate access toessential cancer treatment that also features flexibleand affordable pricing options.Premion operates five excellent cancer centres andGenesisCare plans to open four more centres in areasof need around Queensland. GenesisCare is Australianowned, and currently operates 22 radiotherapypractices across five states.Dr Bernie Mason, former CEO of Premion, has retiredfrom his executive and clinical roles and believesthat GenesisCare will bring a new approach and anew energy directed at providing world-class cancertreatment for the people of Queensland. Patients,referring doctors and health professionals will beable to access new technology and the latest cancertreatment techniques as GenesisCare increasesinvestment in the current treatment centres at:Wesley Hospital Auchenflower, Chermside, Nambour,Southport and Tugun.Over the next 6 months, Premion will be changing itsname to Genesis CancerCare Queensland.Please feel free to phone Kristin Carney, GeneralManager of Genesis CancerCare Queensland, who willbe happy to answer your questions on 07 3326 9511.

TROG 201426th ANNUAL SCIENTIFIC MEETING 24TROG 201425 26th ANNUAL SCIENTIFIC MEETINGFRIDAY 4th APRIL 20147.30 - 8.30am TROG 09.02 (CHISEL) Trial Management Committee D Ball8.00 - 8.30am TROG Consumer Advisory Group J Torony8.45 - 9.05am Health Economics Chair:R McDowall8.45amGetting the most from your health economics data:combining trial and other dataM Haas9.05 - 9.30am Skin Chair:R McDowall9.05am9.10am9.15am9.20am09.03 (MP3): A Phase II Efficacy Study of chemo-radiotherapyin PET stage II and III Merkel Cell Carcinoma ofthe Skin (Open)08.09 (RTN2): A randomised trial of post-operativeradiation therapy following wide excision of neurotropicmelanoma of the head and neck (Open)05.01 (POST): Post-operative concurrent chemoradiotherapyversus post-operative radiotherapy inhigh-risk cutaneous squamous cell carcinoma of thehead and neck (Open)02.01: Randomised clinical trial of surgery versussurgery plus adjuvant radiotherapy for regional controlin patients with completely resected macroscopic nodalmetastatic melanoma (Closed)M PoulsenM FooteS PorcedduB Burmeister9.30 - 10.05am CNS Chair:R McDowall9.30am9.35am9.55am11.02 (SCORAD III): A Randomised phase III study ofsingle fraction radiotherapy compared to multi-fractionradiotherapy in patients with metastatic spinal cordcompression (Open)08.05 (WBRT): Whole Brain Radiotherapy followinglocal treatment of intracranial metastases of melanoma– a randomised phase III trial (Open)06.01: Primary chemotherapy with Temozolomide vsradiotherapy in patients with low grade gliomas afterstratification for genetic 1p loss: a phase III study(Closed)T HoltG FogartyG Ryan10.05 - 10.25am Lung Chair:S Babington10.05am10.10am10.15am10.20am10.25 - 10.50am Morning Tea09.02 (CHISEL): A Randomised phase III trial of highlyconformal hypofractionated image guided (“stereotactic”)radiotherapy (hypoRT) versus conventionally fractionatedradiotherapy (conRT) for inoperable early stage Inon-small cell lung cancer (Open)11.03 (P_LUNG-GP): Randomised phase III trial ofhigh dose palliative radiotherapy (HDPRT) vsconcurrent chemotherapy plus HDPRT (C-HDPRT) in goodperformance status patient with locally advanced orsmall volume metastatic NSCLC - not suitable for radicalchemo-radiotherapy (Open)13.01 (SAFRON II): Stereotactic ablative fractionatedradiotherapy versus radiosurgery for oligometastaticneoplasia to the lung. A randomized Phase II trial(Approved for Development)SABR: Surgery or Stereotactic Ablative Body RadiotherapyFor Early Stage Peripheral Non-Small Cell Lung Cancer(NSCLC) in Patient’s Considered at Higher Risk of SurgicalResection (Approved for Development)D BallM LehmanD BallF Hegi-Johnson10.50 - 12.40pm Past Successes and Looking Forward Chair:S Porceddu10.50am A Year of Achievements J Torony10.55am TROG - Time to re-think its strategic direction and alliances S Porceddu11.15am Quality of Life Working Party Committee Feedback A Macann11.25amInternational Consortium for Health OutcomesMeasurement (ICHOM)I Roos11.35am Clinical Trial Management Workshop Report J Keller11.45am11.55amTechnical Research Workshop Report and ANZRadiation Research Network UpdateReview of the ACDS pilot - a national Dosimetry audit inthe Australian contextR OatesI Williams12.05pm New Technologies and Techniques Committee T Kron12.15pm TROG’s 25 Year History J Denham12.35pm12.40 - 1.00pm LunchASM 2015 AnnouncementMeeting Closure1.00 - 3.00pm TROG Scientific Committee Meeting(committee members only)J MartinB Burmeister

TROG 201426th ANNUAL SCIENTIFIC MEETING 26ACKNOWLEDGEMENTSPLATINUM SPONSORConfidenceConsistencyEfficiencyGOLD SPONSORSElektaInsight OceaniaSILVER SPONSORSAbbVie Pty LtdMerck SeronoJanssenTECHNICAL RESEARCH WORKSHOPVarian Medical Systems AustralasiaListing in alphabetical orderBooth NoAbbvie Pty Ltd 18alphaXRT 7AstraZeneca 9Brainlab 13Elekta 3Ferring Pharmaceuticals 11Fisher & Paykel Healthcare 10InSight 2Janssen 16Merck Serono 15MIM Software Inc 12NL-Tec Pty Ltd 4Nucletron Pty Ltd 5Varian Medical Systems 1RapidPlan – Knowledge-Based PlanningRapidPlan knowledge-based planning opens the door to the nextgeneration of individualised treatment planning by giving clinicians theconfidence to treat a wide range of cancer types using knowledge-basedplanning.By providing access to pre-configured plan models, RapidPlan may helpclinics reduce variability in treatment planning to achieve greater consistency,efficiency and quality in patient care.Streamline your planning process!Disclaimer The information in this document is correct at the time of distribution. The Organisers reserve the right tochange any aspect of the program without prior notice. Please refer to the TROG Website for program updates.Privacy Statement In registering for this event, relevant details may be incorporated into a delegate list for the benefit ofall delegates, sponsors, exhibitors, TROG, and other parties directly related to the Meeting.Varian Medical Systems Australasia Pty Ltd.Sydney, AustraliaPhone +61 2 9485 0100www.varian.com/rapidplan

TROG MISSIONIf you have any ASM enquiries, please contact the Meeting Secretariat:TROG Convention conducts Management world-class New research Zealand involving (CMNZ) radiotherapyto improve T +64 4 479 outcomes 4162 and F +64 quality 4 479 4163 of life for E people dean@cmnzl.co.nz affectedA PO Box 22 233 Khandallah, Wellington 6441, New Zealandby cancer. With collaboration and innovative technologiesTROG www.trog.com.auwill explore advances that influence clinical practice.our missionOUR VALUESCollaboration: TROG conducts We will world-class work with key research stakeholders, involving organisationsand radiotherapy community groups to improve who share outcomes our aim and of defeating quality of cancer. life forQuality: people Our affected research by is guided cancer. by innovation, best practice, rigourand accuracy.Care: We provide the utmost care and consideration for patientsand our families, as valueswell as members of our own team and all thosewith whom we come into contact during the course of our work.Collaboration: We will work with key stakeholders,organisations and community groups who share our aimof defeating cancer.Quality: Our research is guided by innovation, bestpractice, rigour and accuracy.Care: We provide the utmost care and consideration forpatients and families, as well as members of our ownteam and all those with whom we come into contactTrans Tasman Radiation Oncology Group LimitedABN 45 132 672 292during the course of our work.Design: Design Bug I www.designbug.com.au